Christopher Mason is an Oncology physician.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
102 Park St
Cr Wood Cancer Center
Glens Falls, NY 128014403
Telephone
518-926-6620Provider last certified this registry record 10 Feb 2022.
Industry payments
37 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GENZYME CORPORATIONProgram year20252 payments
- Alexion Pharmaceuticals, Inc.Program year20252 payments
- PFIZER INC.Program year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
24.3%Kinase inhibitor7.1%Jakafi38%Calquence22%Brukinsa20%Imatinib Mesylate20%Part D<11 patientsAntimetabolite4.7%Hydroxyurea100%Part D<11 patients+ 4 more classes in this area
Blood & clotting
19.5%Factor Xa inhibitor19.5%Eliquis77%Xarelto23%Part D<11 patientsMetabolism & gastrointestinal
15.7%Corticosteroid7.3%Prednisone100%Part D≥31 patientsSerotonin-3 Receptor Antagonist4.7%Ondansetron Hcl100%Part D≥19 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
10 NIH research awards on record, funded 2011–2026 per NIH RePORTER. The latest:
- Prenatal Traffic-Related Air Pollutants, Placental Epitranscriptomics, and Child Cognition
Columbia University Health Sciences
FY2026$615,144R01ES032818 - Prenatal Traffic-Related Air Pollutants, Placental Epitranscriptomics, and Child Cognition
Columbia University Health Sciences
FY2026$34,729R01ES032818 - Prenatal Traffic-Related Air Pollutants, Placental Epitranscriptomics, and Child Cognition
Columbia University Health Sciences
FY2025$626,463R01ES032818
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”